Market Overview

Allergan Reports Filing of Answer in Federal Court Related to Valeant, Pershing Square's Counterclaims

Related AGN
The Market In 5 Minutes: OPEC's Deal And Gary Johnson's Moment
Benzinga's M&A Chatter for Wednesday September 28, 2016
Nonalcoholic Steatohepatitis: What's The Market Opportunity And Who Are The Major Players? (Seeking Alpha)
Related VRX
Drug Pricing Was Not Even Mentioned At The First Presidential Debate
Drug Price Bubble A Result Of Decade-Long Economic Policy Issues
Walmart's Next Move Against Amazon (Seeking Alpha)

Allergan, Inc. (NYSE: AGN) (“Allergan” or the “Company”) today filed an answer
in the United States District Court for the Central District of California
responding to Valeant Pharmaceuticals International, Inc. (“Valeant”) and
Pershing Square Capital Management, L.P.'s (“Pershing Square”) counterclaims
regarding Allergan's statements on the unsustainability of Valeant's
underlying business model.

The federal court case is Allergan, Inc. v. Valeant Pharmaceuticals
International, Inc., No. 14-CV-1214-DOC (ANx) (C.D. Cal.).

Posted-In: News Hedge Funds Legal Press Releases General


Related Articles (AGN + VRX)

View Comments and Join the Discussion!